Testosterone replacement therapy (TRT) is indicated in hypogonadal symptomatic men, where contraindications to treatment do not exist. The International Society for the Study of the Aging Male recommends a threshold level for consideration for treatment of 11 nmol/l for total testosterone, 0.255 nmol/l for calculated free testosterone and 3.8 nmol/l for bioavailable testosterone. Late onset hypogonadism (the andropause, androgen deficiency in the adult male) which occurs mainly in the latter half of life and identified by a spectrum of symptoms associated with low plasma levels of androgens is becoming an increasingly discussed area of men's health medicine and the largest potential market for TRT. Total and freely circulating plasma levels of testosterone decline by 1 and 2% per annum, respectively, with some men experiencing greater declines than others due to a variety of factors. Using total testosterone data, it has been estimated that 21% men aged between 60 and 80 increasing to 35% of men over the age of 80 are hypogonadal.
Late onset hypogonadism
Testosterone replacement therapy (TRT) is indicated in hypogonadal symptomatic men, where contraindications to treatment do not exist. The International Society for the Study of the Aging Male recommends a threshold level for consideration for treatment of 11 nmol/l for total testosterone, 0.255 nmol/l for calculated free testosterone and 3.8 nmol/l for bioavailable testosterone. 1 Late onset hypogonadism (the andropause, androgen deficiency in the adult male) which occurs mainly in the latter half of life and identified by a spectrum of symptoms associated with low plasma levels of androgens is becoming an increasingly discussed area of men's health medicine and the largest potential market for TRT. Total and freely circulating plasma levels of testosterone decline by 1 and 2% per annum, respectively, with some men experiencing greater declines than others due to a variety of factors. Using total testosterone data, it has been estimated that 21% men aged between 60 and 80 increasing to 35% of men over the age of 80 are hypogonadal. 2 This figure increases to 50% of men over the age of 50 if one uses cutoff values for bioavailable testosterone. 3 The aim of TRT is to normalise plasma testosterone levels. Supraphysiological levels should be avoided and a testosterone preparation that allows dosing and titration to within physiological plasma concentration parameters should be used. 1, 4 Many new formulations of testosterone utilising a variety of routes of administration from transdermal gels to buccal tablets have entered the market over the past 5 years and testosterone prescription sales in the USA have grown by five-fold since 1993.
An ongoing concern is whether TRT initiates prostate cancer, influences carcinogenesis in microscopic precancerous foci or transforms clinically insignificant 'latent' prostate cancer into clinically significant cancer. The question remains unanswered even though testosterone therapies have been available for over 60 years and widespread use and scientific study have failed to illicit a carcinogenic signal.
Prostate cancer
Prostate cancer has the highest prevalence of any nonskin cancer in the human body with approximately 230 000 new cases and 30 000 deaths in the USA predicted for 2004. 5, 6 The incidence of clinically significant prostate cancers has increased in the last 50 years in part due to an ageing population and greater diagnostic testing.
Microscopic foci of cancer ('latent' cancer) are present in 30% men in their 50s and 70% men over the age of 80 years. Essentially all men with circulating androgens will develop microscopic latent cancer if they live long enough, but not all will progress to clinically significant cancer which develops in about 10% men. The chance of dying because of prostate cancer is about 3%.
The incidence of 'latent' prostate cancer is similar in all populations studied throughout the world, being independent of ethnicity, androgen levels, 5 alpha-reductase activity, diet and environmental factors.
The incidence of clinically significant disease varies markedly according to geography and ethnicity. Migration studies have shown that men from countries of low incidence assume the incidence of the adopted country after about 25 years especially after exposure to a western lifestyle, thus inferring an environmental causal component in transformation of latent into clinically significant cancer. Therefore, certain racial groups may have a genetic predisposition to the disease, while environmental factors may influence the aggressiveness.
Prostate cancer is characteristically a slowly progressing tumour with a doubling time of 4-5 years commencing possibly as foci of proliferative inflammatory atrophy (PIA), progressing through precancerous lesions to latent or clinically significant cancer and then beyond (Figure 1 ). Each stage may be dependent upon further exogenous insult resulting in genetic mutations that allow for acceleration of the malignant snowball. With present knowledge genetic predisposition through the presence of susceptibility genes seems to account for nearly 50% of the risk of developing cancer. 8 In addition to inherited susceptibility, others factors including environmental, dietary, infectious and lifestyle issues have been implicated in risk and may have an accumulative effect with age. 6 Whether cancer can arise in men without genetic susceptibility is not known.
Epidemiological data have implicated local infection (prostatitis and sexually transmitted disease) with increased prostate cancer risk and recently it has been proposed that infection and inflammation may play a part in triggering carcinogenesis.
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The role of androgens in prostate cancer
The precise role of androgens in terms of carcinogenesis is unclear. Androgens, primarily through dihydrotestosterone in the prostate, induce cell division and apoptosis and over a lifetime the large number of cell divisions may result in accumulation of spontaneous mutations in prostate cells.
Once malignant transformation has become established, androgens play a role in stimulating malignant cell activity and division and suppression of testosterone levels by medical or surgical castration causes regression of the cancer, at least initially. As such, treatment of hypogonadal men with testosterone in the presence of suspected or confirmed prostate cancer is contraindicated.
Androgen levels and prostate cancer
There is no direct correlation between serum testosterone levels in men and the risk of developing prostate cancer. Indeed, high grade prostate cancer has been associated with low plasma levels of testosterone 12 however, this may be due to a testosterone lowering effect by the presence of prostatic carcinoma. 13, 14 At present there appears to be no compelling evidence that testosterone has a causative role in prostate cancer. [15] [16] [17] [18] [19] Studies using frozen plasma showed no difference in testosterone levels in men who did and did not develop prostate cancer 7-25 years later [17] [18] [19] and it is interesting to note that prostate cancer becomes more prevalent exactly at the time of a man's life when testosterone levels decline. Testosterone exists in bound and unbound states, the former as weakly and strongly bound to albumin and sex hormone binding globulin (SHBG) respectively. SHBG bound testosterone is not bioavailble. SHBG levels are inversely related to plasma testosterone levels and are affected by other factors such as obesity and insulin, thyroid hormone, oestrogen and insulin-like growth factor levels. As higher levels of testosterone are Figure 1 A model of prostrate cancer pathogenesis. 9 TRT for late onset hypogonadism DC Gould and RS Kirby associated with lower levels of SHBG, the latter is thought to be inversely correlated with prostate cancer risk as reported in one study using multivariate analysis. 20 One study revealed that 14% of 77 hypogonadal men with a mean age of 64, normal PSA values and digital rectal examination had prostate cancer on prostate biopsy prior to planned treatment with testosterone. 21 This figure rose to 29% when data for men over 60 were analysed. Gleason scores for all cancers were 6-7. It seems clear therefore that a sizeable group of men being treated for hypogonadism, who have normal PSA levels and rectal examination findings will have occult prostate cancer. If latent cancer is present, it is therefore possible that administering testosterone may increase the chances that a proportion of these cancers progress to become clinically evident.
Androgen metabolism and androgen signalling
Inheritable differences in androgen metabolism and androgen signalling mechanisms play a part in prostate cancer risk.
Prostate cancer and BPH never develop in men castrated before puberty or in men deficient in 5 alphareductase type II iso-enzyme, which converts testosterone in the prostate into the more potent androgen DHT. Such men have raised plasma testosterone levels.
Indeed, the recent large placebo-controlled Prostate Cancer Prevention Trial involving over 18 000 men at low risk of prostate cancer treated for a 7 year period has shown that blocking the conversion of testosterone to DHT with the selective type two 5 alpha-reductase inhibitor, finasteride, reduces the detection of biopsyproven prostate cancer by 25% indicating that reductions in DHT reduce the development of emerging cancer. 22 However, those men treated with finasteride who did develop prostate cancer had a greater chance of developing more aggressive cancers than those given placebo. The reasons for this have not as yet been fully elucidated.
A placebo-controlled trial of dutasteride, a dual inhibitor of 5 alpha-reductase (the REDUCE study) is now underway in men at increased risk of prostate cancer. 23 Dutasteride inhibits both the type 1 and type 2 iso-enzymes of 5 alpha-reductase and reduces the conversion of testosterone to DHT to a greater extent than finasteride. 24 Adverse event data from three large placebo-controlled studies in men with BPH reported a reduction in risk of prostate cancer detection after 27 months of 51%. 25 5 alpha-reductase inhibitors significantly reduce serum and intraprostatic DHT however plasma levels of testosterone increase. The reduction in prostate cancer events with these agents would indicate that DHT and not testosterone is more important in prostate cancer development at least in the early stages of the disease. To support this, ethnic differences in 5 alpha-reductase activity have been reported. The activity is lower in Japanese men than in African-American men who have a higher risk of prostate cancer, inferring a higher activity and therefore a greater conversion of testosterone to DHT in the prostate is associated with an increased risk of cancer.
The androgen receptor
Nucleotide polymorphisms of CAG regions on exon 1 of the androgen receptor gene are common. The number of repeat CAG sequences has been shown to correlate with variability in cancer risk. African-American males have shorter CAG repeats than Asian men and greater cancer risk, while white men have repeat lengths in between. The greater the number of CAG repeats the greater the TRT for late onset hypogonadism DC Gould and RS Kirby length of an amino-acid sequence in the androgen receptor protein and consequent androgen binding capacity. Shorter CAG repeat lengths confer greater activity of the AR and have been associated with an increased risk and earlier onset on cancer. 26, 27 This may suggest that early tumorigenesis depends upon a more active androgen receptor. 10 Androgen receptor expression is increased in the intermediate proliferating cells in prostatic inflammatory atrophy (PIA) and further in prostatic intraepithelial neoplasia (PIN) cells. Such increased expression may enable enhanced androgenic signalling in these early stages in cancer development.
Testosterone replacement therapy and prostate cancer
A number of studies, some placebo-controlled, using various testosterone formulations over periods ranging from several months to 15 years, have not revealed an increased risk of prostate cancer over the background prevalence (see Table 1 ). [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] A recent prospective audit of hypogonadal men screened for prostate cancer prior to and during TRT supports this. 42 Over a period of 15 years, 2200 men with symptoms of androgen deficiency were screened for prostate cancer and investigated for hypogonadism. Of these, 12 (0.5%) were diagnosed as having prostate cancer through digital rectal examination and PSA assessment. In all, 1500 of the original 2200 men had a biochemical diagnosis of hypogonadism and were treated and followed up with digital rectal examinations and PSA measurements on a 3-6 monthly basis for up to 15 years. In all, 10 cases of cancer, all clinically localised, were detected over this time frame of 2100 man years of testosterone treatment (0.48% cases per annum).
The European Randomised Study of Screening for Prostate cancer (ERSSPC) has been running since the mid 1990s. The Finnish component of the study is the largest with 80 000 men enrolled. Men were randomised to a prostate screening arm with PSA analyses at baseline and at 4 years, or a control arm. Analysis of a cohort of men studied revealed that over the 4-year-period the overall prostate cancer detection rate was 2.2% (0.55% per annum). 44 
Conclusions
Testosterone replacement therapy in men with late onset hypogonadism aims to restore low plasma testosterone levels to age-related physiological levels. There has been no conclusive evidence that levels of circulating testosterone in individuals developing prostate cancer are higher than in controls. Indeed some studies have shown that men with low testosterone levels are at greater risk of more aggressive disease. 11 Testosterone has been widely available and prescribed for over 60 years and no carcinogenic signal has emerged through adverse event reporting or clinical study as yet.
The aetiology of prostate cancer remains largely unknown, genetic susceptibility and variations in the androgen signalling pathway, play a role and recently, infection and oxidative stress have been implicated in carcinogenesis. Dihydrotestosterone in men at risk appears to play a part, as studies of 5-alpha reductase inhibitors have been shown to prevent or delay prostate cancer.
If TRT does have a carcinogenic role in early stage disease, then progression is likely to be very slow as prostate cancer has a doubling time of 4-5 years and cell death is not as outpaced by cellular proliferation as in the later stages of prostate cancer when further genetic mutations allow for cancer acceleration.
The Institute of Medicine Committee on Assessing the Need for Clinical Trials of Testosterone Replacement Therapy in the US recently concluded that insufficient evidence exists to justify embarking on a long-term study to determine the risks associated risks associated with testosterone replacement therapy. 45 It has been estimated that a study would need to include 6000 elderly hypogonadal men randomly assigned to testosterone or placebo for 6 years in order to determine whether testosterone treatment increases the risk of prostate cancer by 30%. 45 Instead, the committee recommended first performing short-term controlled studies of the effect of testosterone on several outcomes in elderly men whose testosterone levels were below 300 ng/dl and then only if short-term studies demonstrated efficacy, performing a long-term study to evaluate the risk. It is, therefore, very doubtful that a definitive answer will be forthcoming within the next 10-20 years, if ever.
In the meantime, hypogonadal symptomatic men should be considered for testosterone replacement therapy in line with published guidelines. It is important to exclude prostate cancer before initiation of treatment and to follow-up the patient with regular prostate monitoring and patients should be informed that to date definitive placebo-controlled data relating to testosterone treatment and prostate safety do not exist. A testosterone preparation that achieves physiological plasma levels without supraphysiological escape is preferred.
